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EFFECTS OF NICORANDIL, A NEW ANTIANGINAL K+ 
CHANNEL OPENER, ON LEFT VENTRICULAR FUNCTION IN 
CORONARY ARTERY DISEASE: COMPARISON WITH 
NITROGLYCERIN AND NIFEDIPINE. 
Tetsu Yamakado, Susumu Murayama, Kunihiko Ueda, 
Takeshi Nakano, The First Department of Internal 
Medicine, Mie University, TSU, Japan 
To compare the actions of nicorandil(NR1 on LV 
function in coronary artery disease(CAD) with 
nitroglycerin(NTG) and nifedipine(NIF1, we ana- 
lysed LV grams and pressures(P) (tip manometer) 
in 43 pts before and after intravenous NR(Bmg), 
sublingual NTG(0.6mg) and NIF(20mg). Heart rates 
were held constant by RA pacing. LV volumes were 
derived from frame-by-frame analysis of LV 
grams. Relaxation was assessed by the time con- 
stant (T) of isovolumic P decay. 
Resuits..With similar afterloah reduction, three 
druas auamented systolic function. Different ef- 
fecfs on-preload was noted, which accounted for 
different CO response and perhaps early dias- 
tolic peak filling rate (PFR). Lr relaxation and 
diastolic distensibility evaluated by P-V rela- 
tion were improved with NR and NTG, but not with 
NIF. (*p<0.05, **p<0.01) 
LVSP LVEDP CO LVEDV LVEF PFR T 
NR -14%**-23%** +ll%* -1%” +15%** +2% -7%’ 
NTG-16%**-50%** -8%” -10%“” +lO%** -27%*X -7%” 
NIF-15%** +9% +21%” +2% +lO%** +38%** -2% 
Conclusion.(l) NR is a balanced-type 
vasodilator, which improves LV systolic and 
diastolic fuktion. (2) -Differential-actions are 
observed on LV preload and diastolic function in 
CAD among three antianginal drugs. 
EFFECT OF DILTIAZEM ON SILENT ISCHEMIC EPISODES,PLASMA 
BRADYKININ AND PROSTAGLANDIN METABOLISM 
Eonpei Takase, Akira Kurita, Akimi Uehata, Toshihiko 
Nishioka, Toshiharu Maruyama, Hirokazu Nagayoshi, Hiroyuki 
Hikita, Haruo Nakamura., National Defense Medical College, 
Saitama, Japan 
Plasma bradykinin (BK) and proseaglandin (FG) metabolism 
are related fo angina1 pain modulating system in patients 
(pts> with ischemic heart disease. However,silent ischemic 
episodes (SIE) incidences and the changes of these meta- 
bolites in pts undergoing drug therapy remain unclear. 
Thus, we performed a single blind test wherein, for the 
first two weeks, pts received a placebo and, for the next 
two weeks, 90 mg of diltiazem (DIL) tid. Fifteen pts with 
chronic stable angina (CSA), on grade II per the system of 
rhe Canadian Heart Association, were tested. Their plasma 
DIL levels were measured by liquid chromatography, and the 
effect of DIL was evaluated by treadmill exercise testing 
(EX) and by 48 h Halter monitoring, both performed on the 
same day. And plasma BK and TXB,/6KPGF,, were determined 
by RIA, before and durirg DIL therapy. SIE was defined as 
an episodes of an asymptomatic ST segment depression (ST; 
>l mm, a60 set). DIL increased the EX time, from 400+60 
(SD) set by 13% (pcO.011, Further, Dir. was found to reduce 
episodes of angina, from 1.326.0 I48 h *o 0.5?0.6(pcO.O5). 
DIL 
from 
a however, did not appreciably improve SIE, which went 
.5+8.5 148 h to 7.7t11.7 or the total duration of 
the SIE, which changed from 45?59 min I40 h to 39266. DIL 
also tended to decrease plasma BK levels from 8.3'5.5pg/ml 
by 26%, and TXB,/6KPGF,, from 1.00?0.43 by 40%. 
Conclusion; The discordant effects of DIL on silent and 
painful ischemia indicate that SIE may have a 
different pathogenesis with respect to BK and PG meta- 
bolism. 
DlPYRiDAMOlE PRElREAlMENT PLAYS NO ADDITIVE ROLE TO 
ASPIRIN IN PFIEVENTION OF lHE ACUTE COMPLICATIONS POST 
CORONARY ANGlOPlASTY 
Manfred A Sandier, Paul Joweii, Jeffrey Bruss, Shahriar Yazdanfar, 
Anthony Bracken, John H. Wertheimer, and Morris N. Kotier, 
Cardiology Department, Albert Einstein Medical Center, Philadelphia, 
Pennsytvania 
Dipyridamoie continues to ba a drug prescribed along with 
aspirin in patients undergoing angiopiasty. To date there is no con- 
clusive evidence whether the combination of dipyridamole and aspirin 
is of any benefit over aspirin alone in the prevention of acute com- 
plications in the first 46 hours post angioplasty. This study invokes 
260 patients randomized in a double blinded fashion into Iwo groups. 
Group 1 (n = 134) were assigned enteric coated aspirin 325 mg a 
day and a placebo, one tablet three times a day. Group 2 (n = 146) 
were assigned enferic coated aspirin 325 mg a day and dipyridam- 
oie, 75 mg three times a day. All panicipants were pretreated for at 
least 72 hours. Clinical and anglographic data were similar between 
the groups. Successful angiopiasty was rlormed in 129 patients in 
Group 1 and 141 patients in Group 2. Four end points were sought 
during the first 48 hours after the procedure. Acute 0 wave myocar- 
dial infarction occurred in 2 (1.5%) patients in Group 1 and 1 (0.6%) 
patient in Group 2. Emergency coronary artery bypass graft was re- 
quired for 2 (1.5%) patients in group 1 and 1 (0.6%) patient in Group 
2. Repeat emergerzy coronary angiopiasly was performed on 5 
(3.7%) patients in Group 2 (1.3%) patients in Group 2. There were 
no deaths in either group. Statistically, no significant differences 
were found. When comparing total complications in Group 1 (9) and 
Group 2 (4) a p value of 0.13 was derived. Dipyridam- Conclusion: 
oie in addition to aspirin offers no beneffl over aspirin alone in pre- 
venting eCute complications in the first 48 hours post angioplasty. 
EFFECTS OF NISOLDIPINE ON ISCHEMIA DURI)OG EXERCISE 
TESTING AND DURING D41LY 
Dan Tzivoni, Shmuel Banai , Jesaia Benhorin, Alex 
Gavish, Aharon Medina, Shlomo Roge?, Avraham ?ilberman, 
Shulamit Botvin, Avraham Caspi, Teddy Weiss, Shlomo 
Stern. 
Bikur Cholim Hospital, Jerusalem, Israel. 
This 4-center double-blind placebo-controlled trial 
included 82 pts with stable angina; all had positive 
Bruce protocol exercise test (EXT), and 2;. ischemic 
episodes/day. After a placebo run-in week all pts had a 
72-hour Halter recording and an EXT. Thereafter, 41 pts 
were randomly allocated tq placebo, and 41 to 
nisoldipine (10 mg, BID) for ? weeks, at the end of the 
period 72-hour Ho1 ter 
values during placeh 
snd EXT were repeated. Mean 
treatment in the 2 study 
(PL) and nisoldipine (NL) 
FXT 
Duration, set 
Max ST 4, mm 
Time to I mm ST 1, set 
Time to pain, set 
72-hour Halter 
No. of episodes/pt 
IsLhemic time/pt(min) 
2.6 2.3 .002 
14 11 .DO13 
132 120 N5 
These results indicate that Nisoldipine, 
dihydropiridine calcium antagonist, improved all EXY 
parameters and was partially effective in improving 
ischemia during daily activities. 
